1-2 of 2
Jo-Anne Vergilio
Close
Sort by
Journal Articles

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML

Clinical Trials & Observations
Sheng F. Cai, Ying Huang, Jennie R. Lance, Hsiaoyin Charlene Mao, Andrew J. Dunbar, Samantha N. McNulty, Todd Druley, Yan Li, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark Litzow, Tara Lin, Prapti Patel, Matthew C. Foster, Michael Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy L. Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2024) 8 (2): 429–440.
https://doi.org/10.1182/bloodadvances.2023010563
Published: 2024
Includes: Supplemental data
Journal Articles

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories

Clinical Trials & Observations
Uma Borate, Fei Yang, Richard Press, Amy S. Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C. Pavlick, Luke Juckett, Brianna Norris, Taylor Bucy, Amy Burd, Eytan M. Stein, Prapti Patel, Maria R. Baer, Wendy Stock, Gary Schiller, William Blum, Tibor Kovacsovics, Mark Litzow, James Foran, Nyla A. Heerema, Leonard Rosenberg, Sonja Marcus, Ashley Yocum, Mona Stefanos, Brian Druker, John C. Byrd, Ross L. Levine, Alice Mims
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6048–6054.
https://doi.org/10.1182/bloodadvances.2022009008
Published: 2023
Includes: Supplemental data